Eli Lilly has announced plans to acquire three small vaccine developers, marking a significant expansion in its efforts to address infectious diseases.
This acquisition is expected to bolster Eli Lilly's existing portfolio and contribute to advancements in the vaccine field.
The move underscores the company's commitment to enhancing public health through innovative vaccine solutions.